GoKawiilResearchers engineer bispecific antibodies that degrade GPCRs to block their signaling
Scientists built bispecific antibody constructs that link cell-surface receptors such as AT1R, APJ, A2AR and CCR6 to transferrin receptor 1, redirecting the GPCRs into internalization and degradation pathways. The constructs, described through detailed plasmid and vector engineering, used nanobody and scFv binding domains along with modified antibody Fc regions to test this trafficking-based antagonism approach in cell-based reporter assays.
GoKawiil's interpretation of the reporting above, not reported fact.
If validated further, this approach could offer a new way to shut down disease-linked GPCR signaling by physically removing receptors from the cell surface rather than merely blocking their binding sites, potentially expanding druggable targets beyond traditional small-molecule antagonists. The method's reliance on antibody engineering suggests it could be adapted across many GPCR targets implicated in cardiovascular, metabolic and immune diseases, though its therapeutic viability would depend on further validation beyond these lab assays.
- A new antagonism strategy uses bispecific antibodies to reroute GPCRs into degradation pathways via transferrin receptor 1 engagement.
- The work involved engineering multiple GPCR targets (AT1R, APJ, A2AR, CCR6, RXFP1) with nanobody and scFv binders and modified Fc domains.
- Testing relied on reporter assays including NFAT-luciferase, cAMP and NF-κB systems to measure receptor signaling changes.
Source: nature.com — Rhee, 2026-09-30
Published there as: “GPCR antagonism via rewiring of receptor trafficking and degradation”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.